December 20, 2024
A couple of state updates
Good news from the Alabama Board of Medical Examiners. On June 28, the Alabama Board of Medical Examiners (ALBME) released a declaratory ruling answering questions around physician-compounded GLP-1s. It said, among other things, “Alabama-licensed physicians are required to comply with USP standards when compounding GLP-1 products.” (You can read the full 41-page PDF statement here.)
After a letter from APC urging the board to take that ruling beyond GLP-1 drugs, the ALBME wrote back this past Friday, Dec. 13, explaining that its ruling, in fact, “did apply to all compounding in physicians’ offices even though it focused on semaglutide.”
Pointing out a Massachusetts’ problem. Massachusetts is preparing to implement new licensing requirements for pharmacists that would mandate annual inspections for nonresident compounding pharmacies — twice as often as the current requirement, twice as often as resident compounding pharmacies, and twice as often as any other state.
Naturally, APC registered our concerns with a letter to the Massachusetts Board of Registration in Pharmacy, pointing out that this new requirement “would make Massachusetts the most expensive state for nonresident compounding pharmacy licensure in the country and may lead to unintended consequences for patients in the commonwealth.”
Late-breaking, but Massachusetts has replied that the requirement is statutory. More on this as we investigate further.
